Abstract:
:The American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference Short Course "Translational Challenges in Developing Antibody-Drug Conjugates (ADCs)," held May 24, 2012 in San Diego, CA, was organized by members of the Pharmacokinetics, Pharmacodynamics and Drug Metabolism section of AAPS. Representatives from the pharmaceutical industry, regulatory authorities, and academia in the US and Europe attended this short course to discuss the translational challenges in ADC development and the importance of characterizing these molecules early in development to achieve therapeutic utility in patients. Other areas of discussion included selection of target antigens; characterization of absorption, distribution, metabolism, and excretion; assay development and hot topics like regulatory perspectives and the role of pharmacometrics in ADC development. MUC16-targeted ADCs were discussed to illustrate challenges in preclinical development; experiences with trastuzumab emtansine (T-DM1; Genentech) and the recently approved brentuximab vedotin (Adcetris; Seattle Genetics) were presented in depth to demonstrate considerations in clinical development. The views expressed in this report are those of the participants and do not necessarily represent those of their affiliations.
journal_name
MAbsjournal_title
mAbsauthors
Thudium K,Bilic S,Leipold D,Mallet W,Kaur S,Meibohm B,Erickson H,Tibbitts J,Zhao H,Gupta Mdoi
10.4161/mabs.22909subject
Has Abstractpub_date
2013-01-01 00:00:00pages
5-12issue
1eissn
1942-0862issn
1942-0870pii
22909journal_volume
5pub_type
相关文献
mAbs文献大全abstract::Hepatitis B virus (HBV) produces large (L), middle (M), and small (S) envelope proteins, alternatively referred to as hepatitis B surface antigen (HBsAg). Currently, yeast-derived S protein serves as the preventive vaccine, while hepatitis B immune globulin (HBIG) concentrated from pooled plasma of vaccine recipients ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1134409
更新日期:2016-01-01 00:00:00
abstract::Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite significantly enhanced homogeneity, however, the production of site-specific ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1624127
更新日期:2019-08-01 00:00:00
abstract::Pharmacokinetic (PK) testing of a humanized (κI, VH3 framework) and affinity matured anti-hepatitis C virus E2-glycoprotein (HCV-E2) antibody (hu5B3.κ1VH3.v3) in rats revealed unexpected fast clearance (34.9 mL/day/kg). This antibody binds to the rat recycling receptor FcRn as expected for a human IgG1 antibody and do...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.29809
更新日期:2014-01-01 00:00:00
abstract::Bispecific antibody therapeutics can expand the functionality of a conventional monoclonal antibody drug because they can bind multiple antigens. However, their great potential is counterbalanced by the challenges faced in their production. The classic asymmetric bispecific containing an Fc requires the expression of ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1519631
更新日期:2018-11-01 00:00:00
abstract::A mono-specific antibody may recruit a second antigen binding specificity, thus converting to a dual-specific Two-in-One antibody through mutation at the light chain complementarity-determining regions (CDRs). It is, however, unknown whether mutation at the heavy chain CDRs may evolve such dual specificity. Herein, we...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.28483
更新日期:2014-05-01 00:00:00
abstract::The plasticity of natural immunoglobulin repertoires can be exploited for the generation of phage display libraries. Secondary lymphoid organs, such as the spleen and the lymph nodes, constitute interesting sources of diversity because they are rich in B cells, part of which can be affinity matured. These organs, howe...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.25592
更新日期:2013-09-01 00:00:00
abstract::The current standard treatment for acute myeloid leukemia (AML) is chemotherapy based on cytarabine and daunorubicine (7 + 3), but it discriminates poorly between malignant and benign cells. Dose-limiting off‑target effects and intrinsic drug resistance result in the inefficient eradication of leukemic blast cells and...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1007818
更新日期:2015-01-01 00:00:00
abstract::Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchori...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2020.1807721
更新日期:2020-01-01 00:00:00
abstract::The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of sy...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1685350
更新日期:2020-01-01 00:00:00
abstract::In the present study, we conducted a Phase 1 study of a recombinant anti-EGFR monoclonal antibody (CMAB009) that has the same amino acid sequence as cetuximab. The purpose of this study was to evaluate the safety, pharmacokinetics, and potential benefit of CMAB009 in Chinese patients with advanced chemotherapy-resista...
journal_title:mAbs
pub_type: 杂志文章,随机对照试验
doi:10.4161/mabs.3.1.14021
更新日期:2011-01-01 00:00:00
abstract::Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.1080/19420862.2018.1484977
更新日期:2018-08-01 00:00:00
abstract::The cervical mucosa of women who are highly exposed to HIV-1, yet remain persistently seronegative (HEPS), presents a unique opportunity to study the dynamics of an immune compartment potentially capable of preventing HIV-1 infection. Herein, we provide a detailed characterization of the immunoglobulin repertoire of c...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.3.2.14858
更新日期:2011-03-01 00:00:00
abstract::Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety of malignancies. Sintilimab, a highly selective, fully human monoclonal antibody (mAb), blocks the interaction of PD-1 and its ligands and has demonstrated clinical ben...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1654303
更新日期:2019-11-01 00:00:00
abstract::Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specif...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2020.1714371
更新日期:2020-01-01 00:00:00
abstract::Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a treatment medication for METH abuse. In these studies, we present the preclinical characterization that provided predictive evidence that ch-mAb7F9 may be safe a...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.27620
更新日期:2014-03-01 00:00:00
abstract::Currently, almost all FDA approved therapeutic antibodies (except ReoPro, Lucentis and Cimzia which are Fabs), and the vast majority of those in clinical trials are full-size antibodies mostly in IgG1 format of about 150 kDa size. A fundamental problem for such large molecules is their poor penetration into tissues (e...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.1.1.7480
更新日期:2009-01-01 00:00:00
abstract::Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque path...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.1.2.7829
更新日期:2009-03-01 00:00:00
abstract::Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and invo...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.4.2.19000
更新日期:2012-03-01 00:00:00
abstract::Phage display library technology is a common method to produce human antibodies. In this technique, the immunoglobulin variable regions are displayed in a bacteriophage in a way that each filamentous virus displays the product of a single antibody gene on its surface. From the collection of different phages, it is pos...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.20653
更新日期:2012-07-01 00:00:00
abstract::The neonatal Fc receptor (FcRn) promotes antibody recycling through rescue from normal lysosomal degradation. The binding interaction is pH-dependent with high affinity at low pH, but not under physiological pH conditions. Here, we combined rational design and saturation mutagenesis to generate novel antibody variants...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1633883
更新日期:2019-10-01 00:00:00
abstract::The B cell antigen receptor repertoire is highly diverse and constantly modified by clonal selection. High-throughput DNA sequencing (HTS) of the lymphocyte repertoire (Rep-Seq) represents a promising technology to explore such diversity ex-vivo and assist in the identification of antigen-specific antibodies based on ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1026502
更新日期:2015-01-01 00:00:00
abstract::Antibody engineering must be accompanied by mapping strategies focused on identifying the epitope recognized by each antibody to define its unique functional identity. High throughput fine specificity determination remains technically challenging. We review recent experiences aimed at revisiting the oldest and most ex...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.36144
更新日期:2014-01-01 00:00:00
abstract::Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of thes...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1494105
更新日期:2018-10-01 00:00:00
abstract::Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed t...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.2.1.10677
更新日期:2010-01-01 00:00:00
abstract::Antibodies provide immune protection by recognizing antigens of diverse chemical properties, but elucidating the amino acid sequence-function relationships underlying the specificity and affinity of antibody-antigen interactions remains challenging. We designed and constructed phage-displayed synthetic antibody librar...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1550320
更新日期:2019-02-01 00:00:00
abstract::Fusion to an IgG Fc region is an established strategy to extend the half-life of therapeutic proteins. Most Fc fusion proteins, however, do not achieve the long half-life of IgGs. Based on findings that scFv-Fc fusion proteins exhibit a shorter half-life than the corresponding IgG molecules, we performed a comparative...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1113360
更新日期:2016-01-01 00:00:00
abstract::Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxicities that may be d...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.1080/19420862.2016.1156829
更新日期:2016-05-01 00:00:00
abstract::The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic protection at mucosal surfaces. The choice of expression system for prod...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.2.3.11802
更新日期:2010-05-01 00:00:00
abstract::Ang1 is a soluble ligand to receptor Tie2, and increasing the circulating Ang1 level may improve vascular stabilization under certain disease conditions. Here, we found that the circulating Ang1 level was significantly increased in cynomolgus monkeys treated with non-neutralizing anti-Ang1 antibodies. Improving the an...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1521130
更新日期:2018-11-01 00:00:00
abstract::Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and disc...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.3.1.14169
更新日期:2011-01-01 00:00:00